San Francisco -- Patients with moderate to severe psoriasis can receive efalizumab (Anti-CD11a) continually with no increased toxicity for approximately one year, an ongoing open-label trial shows.
Derm In The News: September 24-30
The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis
The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Discovering Dermatology Times: September 2023 BCC Management Supplement
Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata
2 Clarke Drive Cranbury, NJ 08512